Alumis Corp (ALMS): Price-to-Revenue Ratio

Brandmark of Alumis Inc (ALMS)

The current P/S multiple reflects the valuation dynamics of Alumis Inc. (ALMS), where 104.10 serves as the base parameter value. The anticipated launch of large-scale Phase 3 trials for psoriasis treatment is already priced in. Growth prospects are tied to the development of precision therapies for immune dysfunction and interest from industry behemoths. Business resilience is supported by precision biologics logistics and raw material diversification.

ALMS Alumis Inc. P/S Multiple (06/29/2024 - 11/13/2026)

Analytical breakdowns for Alumis Corp (ALMS)

- current quotes and average value forecast:
Market Price alumis.com|ALMS - Price Target Chart
- stock exchange capitalization data:
Market Value Alumis Corp|ALMS - Total Company Value
- issuer book value statistics:
Net Asset Value per Share Alumis|ALMS - Book Capitalization|Market Value to Equity Ratio alumis.com|ALMS - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Debt to Capital Alumis Inc.|ALMS - Long-Term Debt to Capital|Short-Term Debt to Capital Alumis Pharma|ALMS - Company Debts|Debt to Book Capitalization Ratio Alumis Corp|ALMS - Company Long-Term Liabilities|Company Short-Term Debts Alumis|Quick Liquidity Indicator alumis.com
- earnings and multiples data:
ALMS - Net Profit|Company Profit Forecast Alumis Inc.|ALMS - Price to Earnings Ratio|Market Cap to Projected Earnings Alumis Inc|ALMS - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Alumis Corp|ALMS - Operating profit EBITDA|Net earnings per share for the last four quarters Alumis|ALMS - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months alumis.com|ALMS - Earnings growth in current year|Expected earnings per share growth for next year Alumis Inc.
- issuer revenue and sales details:
ALMS - Company Sales|Company Future Sales alumis.com|ALMS - P/S Multiple|Forward P/S Multiple Alumis Corp
Fundamental company analysis:alumis.com ALMS
Mass-produced product of Alumis Corp

Investors use this multiple to determine the business premium by comparing market capitalization to annual revenue. The index calculation allows for an assessment of the development stage of Alumis Inc. (ALMS), where the full capacity of research centers and contract manufacturing organizations confirms the investment phase, making the price-to-sales ratio analysis a key indicator of future revenue growth expectations.

Who Alumis Inc. competes with

JAZZ - Price to Sales|Price-to-Revenue Ratio Cytokinetics, Incorporated CYTK|PTC Therapeutics Inc - Price-to-Revenue Ratio|SRRK - Price-to-Revenue Ratio|Price to Sales Centessa Corp|DYN: P/S Multiple|Price-to-Revenue Multiple edgewisetx.com EWTX|Market Cap to Revenue RAPP|Price to Sales Zevra Therapeutics Inc ZVRA|P/S Multiple CTNM|P/S Multiple Larimar Corp (LRMR)|Price-to-Revenue Ratio Capricor Therapeutics, Inc. CAPR|entradatx.com - Price-to-Revenue Ratio|PTHS: Market Cap to Revenue|MNOV - P/S Multiple|Serina (SER) - Price-to-Revenue Ratio|Market Cap to Revenue BioXcel Therapeutics Corp|PMN (ProMIS Neurosciences Inc.) - P/S Multiple|Apimeds (APUS) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio AEON Biopharma (AEON)|Price-to-Revenue Coefficient nlspharma.com|Bionomics - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio HUGE|Reata Pharmaceuticals - P/S Multiple